Hydreight Technologies Inc. (TSX: NURS) (OTC: HYDTF) – Q1 2026 Earnings
Hydreight Technologies Inc. (TSX: NURS) (OTC: HYDTF) – Q1 2026 Earnings
Press release and earnings call link
Section 1: Short Tear Sheeet
Hydreight Technologies is a U.S.-focused digital health infrastructure company that helps healthcare brands, med spas, telehealth operators, and direct-to-consumer wellness businesses launch compliant services across all 50 states. Its revenue drivers include platform fees, pharmacy-related transaction volume, provider network access, compliance support, telehealth infrastructure, and VSDHOne, its direct-to-consumer healthcare enablement platform. The company is positioning itself as a compliance-first infrastructure layer for high-growth wellness categories such as weight management, peptides, hormone optimization, longevity, and sexual health. Q1 2026 showed a sharp growth inflection: GAAP revenue rose 449% year over year to $24.9 million, adjusted EBITDA increased to $3.3 million, and net income reached $2.6 million. The call added a much stronger story than the press release: management framed regulation, FDA activity around peptides, and partner ramping as structural growth drivers rather than one-time revenue events.
Quarterly Results
Earnings Release Date: Jun. 1, 2026 (all figures in Canadian dollars)
Stock Price: $4.24
Market Cap: $252.5 million
Q1 2026 sales of $24.93 million vs $4.54 million in the prior year
(quarterly EPS not provided in the press release)
Quick Takeaway
Hydreight Technologies is in a high-growth scaling phase, focused on expanding its digital health infrastructure platform, pharmacy network, VSDHOne platform, and compliance-driven services for direct-to-consumer healthcare operators. The company delivered a breakout Q1 with $24.9 million in revenue, $3.3 million in adjusted EBITDA, positive net income, and a reaffirmed minimum $150 million full-year revenue guide. The main concerns are gross margin compression from pharmacy mix, negative operating cash flow from receivables, and the need to verify that management’s regulatory tailwind thesis translates into repeatable cash-generating growth.
Press Release vs Call Transcript Comparison
The press release is designed to validate the Q1 inflection, while the earnings call tries to convince investors that the inflection is durable. The release is mainly a scorecard: record revenue, record gross profit, adjusted EBITDA, net income, cash, working capital, and platform reach. The call provides the investment thesis behind the numbers: regulatory complexity is pushing customers toward Hydreight, consumer demand is moving toward preventative health and wellness products, and the company’s fixed-cost compliance/provider/technology infrastructure allows more volume to flow through without a matching rise in expenses.
The biggest positive difference is guidance quality. In the call, management says the minimum $150 million revenue outlook is based on existing relationships, current programs, transaction volumes, contracted demand, and existing pharmacy/platform infrastructure, not acquisitions or new geographic expansion. That is a stronger statement than the press release’s broader “on track” language because it gives investors a way to separate execution risk from pipeline speculation.
The biggest caution is the cash-flow and margin mix detail that appears in the call. The press release highlights adjusted EBITDA and net income, but the call shows pharmacy growth is pulling gross margin lower and receivables are consuming working capital. This does not break the thesis, but it changes what investors should track next: not only revenue growth, but gross margin, operating cash conversion, pharmacy receivable days, and whether adjusted EBITDA continues to convert into cash as the year progresses.
Investor Underappreciation Signals
✅Regulation as a growth funnel — Management framed tightening rules in telemedicine, digital health, and compounded medications as a tailwind because smaller or less compliant operators may need Hydreight’s infrastructure to scale legally across states.
✅Guidance appears based on existing activity — The $150 million minimum revenue guide excludes acquisitions, international markets, and new enterprise partnerships, which investors may overlook if they assume the outlook depends on unannounced deals.
✅Product-category leverage — New healthcare categories can be added once to the platform and then offered across the customer base, which could make each new compliant product line more valuable than investors appreciate.
✅Operating leverage is already visible — Revenue grew 67% sequentially with no increase in operating expenses, suggesting the model may scale faster at the EBITDA line than investors focused only on gross margin realize.
✅VSDHOne is still early — Management said the revenue-generating VSDHOne platform is only three quarters into its ramp, which could mean current results are an early proof point rather than peak performance.
✅Peptide/regulatory hearings could create a narrative catalyst — The call’s discussion of FDA peptide hearings adds a concrete hot-trend angle that was not obvious from the press release alone.
✅Customer concentration concern was directly addressed — Management said Q1 was not driven by one customer, one product, or one pharmacy line, which could reduce investor skepticism around the sustainability of the revenue step-up.
✅Working capital is the key watch item — The market may focus on adjusted EBITDA and net income, but the $4.9 million operating cash use tied to pharmacy receivables is the main metric that could determine whether the growth story earns a higher-quality multiple.
Section 2: Supplementary Information
Positive Insights
Negative Insights
Tariff Risk
The transcript does not mention U.S. tariffs, trade policy, import costs, supply-chain tariffs, production shifts, supplier renegotiations, pricing changes tied to tariffs, or tariff-driven effects on revenue and profitability. The company’s discussion focused on regulation, telehealth, compounded medications, pharmacy infrastructure, consumer wellness demand, and operating leverage.
Based on the transcript alone, tariffs do not appear to be a current management concern. The more relevant policy risk is healthcare regulation, especially around digital health, telemedicine, compounded medications, and peptides.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison (Previous Analysis)
In Q4 2025, Hydreight’s story was that the company had spent years building a national healthcare infrastructure platform and had finally proven that VSDHOne could generate meaningful, repeatable revenue. Management’s message was that 2025 was the build-and-prove year, with a larger revenue ramp still embedded in the existing 12,000+ license base.By Q1 2026, that narrative had become much more concrete. Management was no longer mainly asking investors to believe in the platform; it was pointing to $24.9 million of quarterly revenue, $3.3 million of adjusted EBITDA, positive net income, flat operating expenses, and reaffirmed $150 million full-year revenue guidance as evidence that the model is scaling. The story has evolved from “we built the infrastructure and the licenses are ramping” to “the platform is now producing scale, margin expansion, and guidance visibility,” with the main caveat shifting to cash conversion and pharmacy receivables.
Year-over-year comparison
In Q1 2025, Hydreight’s story was still about proving that its compliance-heavy healthcare infrastructure could translate into large-scale VSDHOne order flow. Management was asking investors to understand the complexity of the platform, the onboarding process, and the long-term value of migrating customers into pharmacy-driven recurring revenue streams.
By Q1 2026, the company’s narrative had changed meaningfully. Hydreight was no longer mainly explaining the model; it was pointing to record revenue, positive net income, margin expansion, and full-year guidance as evidence that the model is working. The story evolved from “we have built a compliant healthcare platform with large potential” to “the platform is now scaling, the economics are showing up, and existing partners may still have substantial embedded upside.” The key watch item also changed: in Q1 2025 investors needed proof that VSDHOne would convert into revenue; in Q1 2026 investors need proof that this higher revenue base can convert into durable cash flow while gross margin is pressured by lower-margin pharmacy mix.